Researchers have found that in preclinical models of solid tumors such as breast and colorectal cancer, the combination of an anti-A2AR antibody (CPI-444) with an anti-PD-1 or anti-CTLA-4 antibody inhibits tumor growth and is more effective than monotherapy [237]. Here, ADORA2A is linked to neoplasm.